EMJ GOLD

Novo Nordisk has launched a 7.2 mg semaglutide injection in the US, following FDA approval on 19 March.

Atherosclerotic cardiovascular disease costs global healthcare $680bn per year – the equivalent of Sweden’s entire economy, a new Office of Health Economics report has revealed.

Healthcare is moving into a new phase in which trust, not just treatment, will shape success, says VML Health.

Eli Lilly won FDA approval on 1 April 2026 for a once-daily oral GLP-1, orforglipron.

Pharma companies are facing renewed pressure due to instability linked to the Middle East conflict.

In this roundup, we take a look back at top moments from the pharmaceutical industry from March.

The recent FDA letters to four biologics companies signal a continued rise in enforcement activity.

The collaboration marks one of the largest generative AI-driven partnerships in the pharmaceutical industry to date.

The study moves the non-hormonal endometriosis candidate into mid-stage testing in a field ripe for new options.

The company has announced a multi-year initiative aimed at delivering billions of annualised gross savings by 2028.

The company has selected a site for its new plant to meet what it describes as a “growing demand” for its biologics pipeline.

This collaboration marks the first of its kind for AbbVie and signals a massive national expansion of its ‘Striking Out Cancer’ initiative.

The NHS is sitting on a gold mine of patient data that could, in the ABPI’s view, help rescue the UK’s faltering clinical trials sector.

The FDA has released draft guidance aimed at helping drug developers shift away from traditional animal testing.

Nearly 5 million children die annually from preventable causes linked to poor access to medicines.

Roche is supercharging drug discovery with a major AI expansion to transform how new medicines are developed.

A new fridge-free vaccine for tetanus and diphtheria has shown early promise in human trials.

The share of Americans who feel financially secure about paying for basic healthcare has fallen to its lowest level since 2021.

Co-founders, Prof Ugur Sahin and Prof Özlem Türeci, will depart to establish a new, independent biotechnology company.

The appointment is tied to the company’s “focused innovator” strategy, seeking to combine human expertise with high-performance computing.

The UK Space Agency, MHRA and the CAA have announced a new regulatory roadmap for in-orbit manufacturing of pharmaceuticals.

The collaboration will leverage kyron.bio’s glycoengineering platform to optimise a specific antibody candidate selected by Servier.

The move aims to transform the nation into a strategic centre for global clinical trials and biotechnology innovation in Asia.

As International Women’s Day approaches, data on the global women’s health market paints a mixed picture.

The hunt for new cystic fibrosis therapies is going digital, as the Cystic Fibrosis Foundation taps Antiverse for AI antibody design.

In this monthly news roundup, we take a look back at top moments from the pharmaceutical industry. It’s time to reflect on February 2026.

Novo Nordisk is refitting its facility in Athlone, Ireland, aimed at expanding GLP-1 manufacturing capacity.

The study suggests that the novel compound may offer superior glycaemic control and weight reduction compared with current GLP-1 drugs.

A new report suggests biotech took the lead in UK healthcare M&A in 2025, outpacing pharma and life sciences.

Organisations like Phesi are leveraging digital patient profiles to create digital twins for even the rarest diseases.

Meeting new EU targets for clinical trials could grant 35,000 additional patients access to novel treatments according to a new report.

UCB backs Refold Therapeutics to tackle light chain amyloidosis, a rare disease damaging the heart and kidneys.

The deal is a unified effort to advance a CAR T-cell therapy currently under regulatory review for multiple myeloma.

The FDA has announced that a single clinical trial will now be the default requirement for the approval of novel medicines.

James Van Der Beek’s death from bowel cancer has thrust rising colorectal cancer rates back into the spotlight.

The initiative aims to provide elite athletes with targeted rehabilitation and holistic care for complex or extended recovery needs.

The pharmaceutical industry faces a significant technical bottleneck: only 10% of R&D ends in an approved medicine.

Sanofi’s Board of Directors announced Belén Garijo as the company’s next CEO following the move to not renew the tenure of Paul Hudson.

Bayer and VML Health have launched a campaign challenging the tendency to normalise pain in women’s health.

A new report has found that for Americans living with rare conditions, access to the latest innovations depends on their zip code.